Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in ...

PEN stays on investors' radars due to its strong Thrombectomy business and international growth plans.

Investors looking for stocks in the Medical - Instruments sector might want to consider either Integra LifeSciences (IART) or Penumbra (PEN). But which of these two stocks presents investors with the ...

Penumbra (PEN) could produce exceptional returns because of its solid growth attributes.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Investing in large-cap MedTech stocks like MCK, PEN, CAH and PEN can be profitable for investors in 2025.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Shares of Penumbra Inc PEN recovered slightly in early trading on Tuesday, after a week of correction.

MASI, PEN and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and su...

Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

PEN stays on investors' radars due to its robust portfolio expansion and international growth plans.

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and Penumbra (PEN). But which of these two stocks presents investors with the ...

Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Penumbra (PEN) possesses solid growth attributes, which could help it handily outperform the market.

Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

The third-quarter results reflect another strong performance by Penumbra's U.S. thrombectomy business.

Penumbra, Inc. (NYSE:PEN ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - C...

While the top- and bottom-line numbers for Penumbra (PEN) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compa...